The FDA approved mFLUSIVA, the first mRNA-based flu vaccine for adults 50 and older, manufactured by Moderna. The shot showed strong efficacy in preventing serious illness in people ages 50 to 64 in phase 3 clinical trials, with accelerated approval granted for those 65+. It uses the same mRNA technology that powered COVID-19 vaccines — meaning faster, more targeted protection heading into the 2026–2027 flu season.

Side effects: More research is still being conducted...